A randomized double blind controlled proof of concept study of the efficacy and safety of Valcyte [valganciclovir] as an add-on therapy in patients with malignant glioblastoma with successful surgical resection of at least 90 % of the initial tumor and CMV infection demonstrated histologically and immunohistochemically.

Trial Profile

A randomized double blind controlled proof of concept study of the efficacy and safety of Valcyte [valganciclovir] as an add-on therapy in patients with malignant glioblastoma with successful surgical resection of at least 90 % of the initial tumor and CMV infection demonstrated histologically and immunohistochemically.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalovirus infections; Glioblastoma
  • Focus Therapeutic Use
  • Acronyms VIGAS
  • Most Recent Events

    • 01 Sep 2013 Results published in the International Journal of Cancer.
    • 02 Oct 2012 Primary endpoint 'Magnetic-resonance-imaging-outcomes' has not been met.
    • 11 Sep 2012 Primary endpoint 'Tumour-volume' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top